In the context of cancer, HLA Class II molecules are involved in the immune system's ability to recognize and attack tumor cells. Tumors often employ mechanisms to evade immune detection, such as downregulating HLA molecules or altering antigen presentation pathways. Understanding the interaction between HLA Class II and cancer can lead to better immunotherapeutic strategies. Studies have shown that the expression of HLA Class II on tumor cells can be associated with improved prognosis in certain cancers, as it may enhance the visibility of tumors to the immune system.
